Shanghai, China & New Jersey, USA (November 11th, 2024) — Oricell Therapeutics (Oricell), a clinical-stage biotech company dedicated to leading in oncology immunotherapy innovation and focusing on developing advanced cell therapies, announces details from Saturday’s oral presentation of its bispecific BCMAxGPRC5D CAR-T targeting heterogeneous multiple myeloma (MM), at the 39th Society for Immunotherapy of Cancer Annual Meeting (SITC 2024) in Houston, TX. Additionally, the abstract has been selected for inclusion in the SITC Top 100 abstracts.
Shanghai, China & New Jersey, USA (November 5th, 2024) — Oricell Therapeutics (Oricell), a clinical-stage biotechnology company aiming to lead in oncology immunotherapy innovation and focusing on developing advanced cell therapies, today announced an upcoming oral presentation for its bi-specific BCMAxGPRC5D CAR-T therapy targeting heterogeneous multiple myeloma (MM), at the 39th Society for Immunotherapy of Cancer Annual Meeting (SITC 2024) being held at November 6-10, 2024 in Houston, TX., The pre-clinical studies on the dual CAR-T indicate its potential to address unmet medical needs in both newly diagnosed and relapsed/refractory MM patients.
Shanghai, China & New Jersey, USA (October 17th, 2024) — Oricell Therapeutics, a clinical-stage biotechnology company aiming to lead in oncology immunotherapy innovation and focusing on developing advanced cell therapies, announced the clearance of its investigational new drug (IND) application from China's National Medical Products Administration (NMPA) for its proprietary Dual AND Logic Claudin 18.2/Mesothelin (MSLN) autologous chimeric antigen receptor (CAR-T) therapy, OriC613. This approval grants Oricell the authority to initiate a Phase I clinical trial for advanced solid tumors, including gastric cancer, in China.
SHANGHAI, August 20th, 2024 — Oricell Therapeutics is pleased to announce the establishment of its Scientific Advisory Board (SAB) , which has been bolstered by the appointment of two esteemed experts in the field of multiple myeloma, Dr. Kenneth C. Anderson and Dr. Shaji Kumar. Such appointments strengthen Oricell’s global strategies of developing novel therapeutics especially its proprietary CAR-T products to combat malignancies, with a particular emphasis on the field of multiple myeloma(MM).
SHANGHAI, NEW JERSEY - July 15th, 2024 - Oricell Therapeutics, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation (FTD) for OriCAR-017, a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM). This designation is expected to accelerate the progress of clinical trials and the New Drug Application (NDA/BLA) review process. Prior to this, the FDA has granted Orphan Drug Designation (ODD) and has cleared an Investigational New Drug Application (IND) for OriCAR-017.
New Jersey, USA, and Shanghai, China — June 5, 2024 — Oricell Therapeutics, a pioneering clinical-stage biopharmaceutical company, has presented the two-year long-term follow-up results of OriCAR-017, an open-label Phase I study evaluating GPRC5D-targeted CAR-T therapy in patients with relapsed/refractory multiple myeloma (RRMM), in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Shanghai, New Jersey - May 24, 2024 - Oricell Therapeutics has announced the full abstract (Abstract ID:7511) detailing the two-year long-term follow-up results of OriCAR-017, an open-label Phase I study evaluating GPRC5D targeting CAR-T therapy in patients with Relapsed/Refractory Multiple Myeloma (POLARIS), is now available on the 2024 American Society of Clinical Oncology (ASCO) official website.
SHANGHAI, NEW JERSEY — May 16th, 2024 — Oricell Therapeutics, a clinical-stage biotechnology company at the forefront of developing innovative therapies for life-threatening diseases, is pleased to announce its participation in the upcoming ASCO 2024 Annual Meeting（31th May-4th June). The Company will deliver an oral presentation and two poster presentations, highlighting updated clinical data from POLARIS study that evaluates OriCAR-017, a GPRC5D targeted CAR-T program, as well as showcasing other novel therapeutic approaches.
SHANGHAI, NEW JERSEY, Jan 29th, 2024 – Oricell Therapeutics (Oricell), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for OriCAR-017 for patients with relapsed/refractory multiple myeloma (R/R MM). OriCAR-017 is a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D. The therapy leverages Oricell's proprietary platforms including Ori®Ab antibodies, Ori®CAR construct and unique CMC know-how to achieve optimal binding and superior persistence and anti-tumor efficacy out of rejuvenated CAR-T cells. The IND enables Oricell to initiate the clinical development for OriCAR-017 in the US immediately.
沪公网安备 31011502019994号